Therapy Areas: Cardiovascular
Thalia Therapeutics acquires Sanmirna and raises GBP2.75m to advance AML RNA therapy
24 June 2026 - Biotechnology company Thalia Therapeutics plc (AIM: THAT) disclosed on Wednesday that it has agreed to acquire clinical-stage oncology company Sanmirna Therapeutics Inc, adding its lead...
Novo Nordisk Foundation funds European initiative to accelerate drug discovery for cardiometabolic diseases
22 June 2026 - The Novo Nordisk Foundation, a philanthropic enterprise foundation created by Danish pharmaceutical company Novo Nordisk A/S (CPH:NOVO-B) (NYSE:NVO), announced on Friday that it is fund...
Kalohexis presents dual MC3R/MC4R activation data at ENDO 2026
16 June 2026 - Clinical-stage biotechnology company Kalohexis Inc announced on Monday that data supporting dual melanocortin-3 receptor/melanocortin-4 receptor (MC3R/MC4R) activation as a novel mechan...
Bayer reports positive Phase III FIND-CKD results for Kerendia in non-diabetic chronic kidney disease
5 June 2026 - German pharmaceutical and life sciences company Bayer AG (ETR:BAYN) (OTC:BAYRY) on Friday reported full results from the Phase III FIND-CKD trial evaluating Kerendia (finerenone) in adul...
Lupeng Pharmaceutical's rocbrutinib receives Chinese approval to treat R/R mantle cell lymphoma
5 June 2026 - Chinese clinical-stage company Lupeng Pharmaceutical Ltd announced on Thursday that China's National Medical Products Administration (NMPA) has granted accelerated approval to rocbr...
Medtronic invests in ICE technology companies to expand cardiac ablation portfolio
3 June 2026 - Healthcare technology company Medtronic plc (NYSE: MDT) announced on Wednesday that it is making strategic investments in two privately held intracardiac echocardiography (ICE) catheter ...